ANXA1 (Annexin A1) is a calcium-dependent phospholipid-binding protein belonging to the annexin superfamily, widely recognized for its role in regulating inflammation, cellular signaling, and membrane repair. Initially identified as a glucocorticoid-inducible protein, ANXA1 modulates anti-inflammatory responses by inhibiting phospholipase A2 and neutrophil migration, while also influencing cell proliferation, apoptosis, and differentiation. It is expressed in various tissues, including immune cells, epithelial cells, and certain cancer cells, where its dysregulation has been linked to pathological conditions such as cancer, autoimmune disorders, and neurodegenerative diseases.
ANXA1 antibodies are essential tools for detecting the protein’s expression, localization, and functional interactions in research. These antibodies are developed using immunogens derived from specific regions of ANXA1. such as its unique N-terminal domain or conserved C-terminal core. They enable applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. In cancer research, ANXA1 antibodies help assess its dual role as a tumor suppressor or promoter, depending on context, with implications for breast cancer, glioblastoma, and prostate cancer. Specificity validation via knockout controls or blocking peptides is critical due to potential cross-reactivity with other annexins or post-translational modifications. Commercial ANXA1 antibodies vary in host species (e.g., mouse, rabbit), clonality (monoclonal/polyoclonal), and conjugate tags, allowing flexibility for experimental design. Their utility extends to exploring ANXA1’s therapeutic potential, including targeted anti-inflammatory drug development.